<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660838</url>
  </required_header>
  <id_info>
    <org_study_id>2-094-20</org_study_id>
    <nct_id>NCT04660838</nct_id>
  </id_info>
  <brief_title>Intervention to REduce anticholinerGic burdEN in oldER pATiEnts (REGENERATE) Aged 65 Years and Older</brief_title>
  <acronym>REGENERATE</acronym>
  <official_title>Intervention to REduce anticholinerGic burdEN in oldER pATiEnts (REGENERATE) Aged 65 Years and Older: A Non-randomised Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aberdeen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medications with anticholinergic properties are frequently prescribed for several conditions&#xD;
      in older age; for example cardiovascular drugs (e.g. digoxin, furosemide), urologicals (e.g.&#xD;
      darifenacin, oxybutynin) and anti-parkinsonism drugs (e.g. benztropine, trihexyphenadyl). It&#xD;
      has been shown that increasing anticholinergic burden (ACB) can cause poor health-related&#xD;
      outcomes, but there are still uncertainties around whether it is possible or acceptable to&#xD;
      stop medication with high ACB and/or switching to another medication with no or low&#xD;
      anticholinergic burden, the effect on health-related outcomes of such an approach, the most&#xD;
      appropriate person to deliver this intervention or the health care setting in which it should&#xD;
      take place.&#xD;
&#xD;
      The term 'deprescribing' is the process of intentionally stopping a medication or reducing&#xD;
      its dose to improve the person's health or reduce the risk of adverse side effects. There is,&#xD;
      however, limited research regarding deprescribing. Previously, researchers have suggested&#xD;
      deprescribing is a systematic process of identifying and discontinuing drugs in instances in&#xD;
      which existing or potential harms outweigh existing or potential benefits within the context&#xD;
      of an individual patient's care goals, current level of functioning, life expectancy, values,&#xD;
      and preferences. However, there are not many studies about implementation of appropriate&#xD;
      interventions to reduce ACB in older patients (aged 65 year and over).&#xD;
&#xD;
      The aim of this non-randomised study is to explore the feasibility of delivering an&#xD;
      intervention to reduce the ACB in older patients by deprescribing or switching to inform a&#xD;
      future definitive clinical trial. This is a single-arm, open feasibility study conducted in&#xD;
      primary and secondary care involving older patients. Mixed method (routine data,&#xD;
      questionnaires and interviews) will be used in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment of patients from GP practices and hospitals</measure>
    <time_frame>3 months</time_frame>
    <description>The number of patients who are invited to study and the number of patients agree to take part and refuse with reasons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The completion rate of baseline and follow up data</measure>
    <time_frame>3 months</time_frame>
    <description>The patients background information, medical history, medications will be recorded at baseline and at 3 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of medication changes recommended and the number implemented</measure>
    <time_frame>3 months</time_frame>
    <description>Time taken to do consultations and acceptance as well as rejection with reasons of doctor from pharmacist recommendations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The sustainability of intervention (i.e. those remained on same drugs at 6 week and 3 months post intervention)</measure>
    <time_frame>3 months</time_frame>
    <description>Information on patients who remained on reduced regimen and those who went back on the drug or need extra-drug and reasons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The acceptability of intervention to patients and health care professional stakeholders</measure>
    <time_frame>3 months</time_frame>
    <description>Semi-structured interviews with patients and health care professionals</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Anticholinergic Adverse Reaction</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ACB intervention</intervention_name>
    <description>Stopping and/or switching ACB medication to an alternative</description>
    <other_name>Stopping and/or switching ACB medication</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for stopping and/or switching medications&#xD;
&#xD;
        Patients who are:&#xD;
&#xD;
          -  aged 65 and over&#xD;
&#xD;
          -  able to provide informed consent.&#xD;
&#xD;
          -  on one or more long-term drugs (have been prescribed a minimum 6 weeks) with ACB&#xD;
             potential (Anticholinergic Cognitive Burden scale ≥3) (defined according to Boustani&#xD;
             et al (Boustani, Campbell et al. 2008)&#xD;
&#xD;
        Exclusion Criteria for stopping and/or switching medications&#xD;
&#xD;
        Patients who:&#xD;
&#xD;
          -  are without capacity to provide informed consent.&#xD;
&#xD;
          -  have severe mental illness [such as diagnosis of severe anxiety, severe depression,&#xD;
             severe dementia etc.].&#xD;
&#xD;
          -  are terminally ill (life expectancy less than 6 months).&#xD;
&#xD;
          -  in opinion of responsible clinician are not suitable.&#xD;
&#xD;
          -  are taking part in another study.&#xD;
&#xD;
        Health care professional inclusion criteria for interviews&#xD;
&#xD;
        - Professionals: doctors (consultants, GPs), pharmacist in primary and secondary care&#xD;
        involved in the care of patients aged 65 and over on polypharmacy regimes/likely to have&#xD;
        anticholinergic burden and have taken part in the study by delivering the intervention&#xD;
&#xD;
        Patients inclusion criteria for interviews&#xD;
&#xD;
        - Patients: patients aged 65 years and over who met eligible criteria and have taken part&#xD;
        in the REGENERATE study will be selected.&#xD;
&#xD;
        Exclusion criteria for interviews&#xD;
&#xD;
        - Participants who cannot understand English fluently&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Athagran Nakham, Pharm.D.</last_name>
    <phone>01224277856</phone>
    <email>r03an17@abdn.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peterculter Medical Practice</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB14 0RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Sillito, MPharm</last_name>
      <phone>01224733535</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Best O, Gnjidic D, Hilmer SN, Naganathan V, McLachlan AJ. Investigating polypharmacy and drug burden index in hospitalised older people. Intern Med J. 2013 Aug;43(8):912-8. doi: 10.1111/imj.12203.</citation>
    <PMID>23734965</PMID>
  </reference>
  <reference>
    <citation>BOUSTANI, M., CAMPBELL, N., MUNGER, S., MAIDMENT, I. and FOX, C., 2008. Impact of anticholinergics on the ageing brain: a review and practical application. Aging Health, 4(3), pp. 311-320.</citation>
  </reference>
  <reference>
    <citation>Cancelli I, Beltrame M, Gigli GL, Valente M. Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patients. Neurol Sci. 2009 Apr;30(2):87-92. doi: 10.1007/s10072-009-0033-y. Epub 2009 Feb 20. Review.</citation>
    <PMID>19229475</PMID>
  </reference>
  <reference>
    <citation>Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging. 1993 Jul-Aug;3(4):335-48. Review.</citation>
    <PMID>8369593</PMID>
  </reference>
  <reference>
    <citation>Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, Boustani M, Kwok CS, Glover M, Koopmans I, Campbell N. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014 Sep;43(5):604-15. doi: 10.1093/ageing/afu096. Epub 2014 Jul 19. Review.</citation>
    <PMID>25038833</PMID>
  </reference>
  <reference>
    <citation>Gorup E, Rifel J, Petek Šter M. Anticholinergic Burden and Most Common Anticholinergic-acting Medicines in Older General Practice Patients. Zdr Varst. 2018 Jun 21;57(3):140-147. doi: 10.2478/sjph-2018-0018. eCollection 2018 Jun.</citation>
    <PMID>29983780</PMID>
  </reference>
  <reference>
    <citation>Green AR, Reifler LM, Bayliss EA, Weffald LA, Boyd CM. Drugs Contributing to Anticholinergic Burden and Risk of Fall or Fall-Related Injury among Older Adults with Mild Cognitive Impairment, Dementia and Multiple Chronic Conditions: A Retrospective Cohort Study. Drugs Aging. 2019 Mar;36(3):289-297. doi: 10.1007/s40266-018-00630-z.</citation>
    <PMID>30652263</PMID>
  </reference>
  <reference>
    <citation>Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2013 Mar;68(3):271-8. doi: 10.1093/gerona/gls176. Epub 2012 Sep 14.</citation>
    <PMID>22982689</PMID>
  </reference>
  <reference>
    <citation>López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic Drugs in Geriatric Psychopharmacology. Front Neurosci. 2019 Dec 6;13:1309. doi: 10.3389/fnins.2019.01309. eCollection 2019. Review.</citation>
    <PMID>31866817</PMID>
  </reference>
  <reference>
    <citation>Nakham A, Myint PK, Bond CM, Newlands R, Loke YK, Cruickshank M. Interventions to Reduce Anticholinergic Burden in Adults Aged 65 and Older: A Systematic Review. J Am Med Dir Assoc. 2020 Feb;21(2):172-180.e5. doi: 10.1016/j.jamda.2019.06.001. Epub 2019 Jul 24. Review.</citation>
    <PMID>31351858</PMID>
  </reference>
  <reference>
    <citation>OLASEHINDE-WILLIAMS, O., July, 2020-last update, Deprescribing guide. Available: https://southendccg.nhs.uk/your-health-services/healthcare-professionals/medicines-management/medicines-management-resources/2308-deprescribing-guide/file [April/03, 2020].</citation>
  </reference>
  <reference>
    <citation>Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Med J Aust. 2014 Oct 6;201(7):386-9.</citation>
    <PMID>25296058</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anticholinergic burden</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

